|Mr. Michael R. McDonnell CPA||Exec. VP & CFO||1.86M||N/A||1964|
|Ms. Susan H. Alexander Esq.||Exec. VP, Chief Legal Officer & Sec.||1.79M||N/A||1957|
|Mr. Christopher A. Viehbacher||Pres, CEO & Director||N/A||N/A||1960|
|Ms. Robin C. Kramer||Sr. VP & Chief Accounting Officer||N/A||N/A||1966|
|Ms. Nicole Murphy||Head of Pharmaceutical Operations & Technology||N/A||N/A||N/A|
|Mr. Michael Hencke||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Natacha Gassenbach||Chief Communication Officer & Head of Corp. Affairs||N/A||N/A||N/A|
|Dr. Ginger Gregory||Exec. VP & Chief HR Officer||N/A||N/A||1968|
|Dr. Anabella Villalobos Ph.D.||Head of Biotherapeutics & Medicinal Sciences||N/A||N/A||1959|
|Dr. Sanjay Jariwala||Sr. VP of Worldwide Medical||N/A||N/A||N/A|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 3; Compensation: 9.